Postoperative Nausea and Vomiting (PONV) Market Growth Drivers & Forecast 2033

Postoperative Nausea and Vomiting (PONV) by Type (/> Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacologic Treatment, Others), by Application (/> Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Postoperative Nausea and Vomiting (PONV) Market Size | CAGR 4.2 Forecast 2033

Postoperative Nausea and Vomiting (PONV) Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Postoperative Nausea and Vomiting (PONV) Market Overview

Postoperative Nausea and Vomiting (PONV) comprises one of the most frequent and distressing anesthesia-related complications, driving measurable increases in length of stay, readmissions, and overall cost per surgical case. The Postoperative Nausea and Vomiting (PONV) market size—estimated at USD 2.6 billion in 2025—encompasses 5-HT3 receptor antagonists, NK-1 antagonists, corticosteroids, dopamine antagonists, and multimodal combination therapies used across inpatient and ambulatory surgical settings. Rising procedure volumes, mandatory adoption of ERAS protocols, and heightened patient-reported outcome requirements underpin a growth outlook of ~6% CAGR through 2033, lifting the global market forecast to roughly USD 4.4 billion.

Loading chart…

Technology shifts toward long-acting NK-1–based fixed-dose combinations and app-driven risk scoring are redefining prophylactic algorithms, while stricter regulatory mandates for outpatient PONV quality metrics are accelerating hospital formulary upgrades. Supply-chain dynamics remain favorable for generics (ondansetron, dexamethasone), yet innovators leverage patent-protected NK-1 combos and IV-to-oral switches to command premium pricing. North America captured ~41% share in 2025 thanks to high laparoscopic volume and reimbursement for multimodal therapy, whereas Asia-Pacific is forecast to outpace all regions at 7.6% CAGR, propelled by booming medical tourism, expanding insurance coverage, and rapid adoption of ERAS society guidelines across India and China.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	2.50 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acacia Pharma; F. Hoffmann-La Roche; Novartis; Ani Pharmaceuticals; Camurus; Sanofi; Helsinn Holding; Eisai; Merck; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Ambulatory surgery surge is expanding the Postoperative Nausea and Vomiting (PONV) market size; same-day discharge protocols require zero-tolerance PONV control, prompting hospitals to adopt combination 5-HT3/NK-1 regimens with faster onset IV formulations, pushing the segment’s growth forecast above 8 % CAGR through 2030.

Value-based purchasing penalties in the U.S. and Germany now tie DRG reimbursements to unplanned admissions linked to PONV-related dehydration or aspiration; this regulatory nudge is accelerating cap-ex allocation toward closed-loop anesthesia monitors that titrate propofol to predicted PONV risk, directly lifting attach rates for high-margin drug–device bundles.

Restraints2 items

Off-patent cliff for palonosetron and aprepitant has compressed average selling prices >45 % since 2022, eroding gross margin even as unit volumes rise; generic saturation forces innovators to defend share via bundled risk-sharing contracts, limiting reinvestment in next-generation molecules.

Supply-chain concentration on a single Chinese API producer for NK-1 antagonists exposes formulators to ≥6-month qualification cycles and double-digit cost inflation when regulators tighten GMP audits, delaying new product launches and capping regional revenue upside.

Opportunities2 items

Digital therapeutic algorithms that integrate real-time BIS monitoring with machine-learned phenotypic data can predict PONV >30 min before emetic onset, creating a software-as-a-medical-device revenue stream priced per-procedure and unlocking recurrent high-margin annuity beyond the pill.

Asia-Pacific ambulatory chains (India, Thailand, Vietnam) are adding >2 000 new ORs annually yet under-index on PONV prophylaxis (<25 % vs 70 % in OECD); tiered-pricing agreements with private payors represent a US$180 m whitespace for fixed-dose combinations before local generics scale.

Challenges2 items

Anesthesiologist shortage in the U.S. and Western Europe—projected deficit 19 k by 2027—stretches staffing ratios, reducing protocol compliance for multi-modal PONV management and suppressing premium drug uptake despite hospital C-suite willingness to pay.

Reimbursement heterogeneity across EU national health systems forces manufacturers to negotiate country-specific risk-sharing deals (e.g., dose-caps, outcome refunds), fragmenting revenue visibility and complicating pan-regional supply chain planning for the Postoperative Nausea and Vomiting (PONV) market.

Market Segmentation

Loading chart…

Postoperative Nausea and Vomiting (PONV) segmentation by type revolves around the pharmacologic classes employed for prophylaxis and rescue. 5-HT3 receptor antagonists remain the largest revenue anchor, driven by generically available ondansetron and newer high-affinity agents that sustain market share through superior q.i.d. dosing convenience. NK-1 receptor antagonists constitute the fastest-expanding niche; their longer half-life shifts the economic value toward high-risk laparoscopic and gynaecological centres willing to pay a premium to shorten post-anaesthesia care unit (PACU) stay. Corticosteroids, primarily dexamethasone, generate high-volume, low-margin income owing to off-label utilisation guidelines, whereas dopamine antagonists (e.g., droperidol) face supply-led contraction triggered by regulatory black-box warnings. Dual- and triple-combination therapies now account for roughly one-third of segment value, illustrating prescribers’ migration toward multimodal protocols that raise average selling prices and, by extension, the aggregate market taxonomy ceiling.

Application-based splits map directly to surgical volume and anaesthetic complexity. Postoperative Nausea and Vomiting (PONV) market spend within general surgery is propelled by lengthy bowel cases requiring volatile anaesthetics and post-operative opioids; the segment captures the greatest share of both 5-HT3 and NK-1 vials. Orthopaedic theatres follow, where patient-controlled analgesia elevates emetogenic risk and justifies routine triple-agent prophylaxis. Gynaecology–especially laparoscopy–exhibits the highest incidence (>60 %), translating into per-capita drug expenditure 1.8× the hospital mean. ENT and plastic surgery represent comparatively low-volume but profitable settings because ambulatory centres bundle PONV prevention into 23-hour discharge pathways, accepting higher drug acquisition costs to avoid costly overnight conversions. Ophthalmology sits at the periphery, accounting for minimal dollar share yet growing in paediatric strabismus sub-segments where even a single emetic episode is financially punitive.

Postoperative Nausea and Vomiting (PONV) Segmentation Breakdown11 items

Type

/> Serotonin Antagonists

Steroids

Dopamine Antagonists

NK-1 Receptor Antagonists

Non-pharmacologic Treatment

Others

Application

/> Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Regional Insights

Loading chart…

North America retains largest share of the global Postoperative Nausea and Vomiting (PONV) market, propelled by entrenched Enhanced Recovery After Surgery (ERAS) protocols, mandatory quality metrics that penalize PONV readmissions, and a payer mix that rewards value-based purchasing. Regional forecast indicates 4.2% CAGR to 2030, underpinned by hospital capital investments in closed-loop anesthesia and digital therapeutics.

Asia Pacific is the fastest-growing region, registering 7.5% CAGR; rising ambulatory surgery, broadening reimbursement for serotonin antagonists, and government-backed medical tourism corridors are accelerating adoption. China’s volume-based procurement reforms are compressing unit prices, yet overall PONV market growth is offset by procedure volume expansion and tier-3 hospital upgrades.

Europe’s momentum is shaped by HTA bodies mandating cost-utility data for antiemetics, a shift toward multimodal PONV prophylaxis in day-case settings, and sustainability directives favoring propofol-based anaesthesia to reduce desflurane emissions. Western Europe dominates share, but Central & Eastern Europe are closing the gap through EU cohesion fund investments.

Latin America shows resilient demand despite macro volatility; Brazil and Mexico allocate ring-fenced public tenders for 5-HT3 inhibitors, while private chains standardize risk-stratified PONV protocols to attract insured patients. Middle East & Africa growth is uneven—Gulf states leverage oil-backed health budgets to procure newest NK1 receptor antagonists, whereas Sub-Saharan progress hinges on NGO-led surgery initiatives and WHO essential medicine list updates.

Competitive Landscape

The Postoperative Nausea and Vomiting (PONV) competitive landscape is moderately consolidated, with a handful of global innovators holding most late-stage assets while numerous regional manufacturers supply low-cost 5-HT3 antagonists and steroid anti-emetics. Multinationals such as Helsinn, Eisai, Merck and Acacia rely on patented or recently off-patent molecules (e.g., rolapitant, palonosetron, amisulpride) to defend price tiers above $40 per peri-operative dose, whereas a diffuse set of Indian, Chinese and Latin American generic houses compete at <$5 per treatment. Regulatory certification (US FDA, EMA, Japan PMDA) and hospital formulary contracts are the primary levers for volume access; tenders in the EU5, Nordics and Japan increasingly reward suppliers able to bundle PONV prophylaxis with post-operative pain or anaesthesia adjuvants, tightening margin discipline across the value chain.

To offset reimbursement pressure, players are pursuing indication expansions into chemotherapy-induced nausea and paediatric surgery, co-formulations with IV analgesics, and 30-day outpatient compliance packs. M&A activity targets late-phase or recently launched NK-1 receptor antagonists to widen the prophylaxis window, while partnerships with ambulatory surgery centres secure pull-through in high-turnover day-case settings. Differentiation now hinges on faster onset IV formulations, longer half-life enabling single-dose administration, and ready-to-use pre-filled syringes that reduce pharmacy reconstitution costs. Rising API prices for ondansetron and regulatory scrutiny of QT-prolongation liabilities continue to compress gross margins, forcing suppliers either to integrate backward into active ingredient production or to localise fill-finish in lower-cost markets.

Acacia Pharma: hospital-focused launch of amisulpride IV for rescue PONV

F. Hoffmann-La Roche: licensing oral NK-1 for chemo-linked PONV expansion

Novartis: Sandoz unit drives cost-down ondansetron through tender bids

Ani Pharmaceuticals: vertical integration of API plant to offset price erosion

Camurus: long-acting depot granisetron for ambulatory surgery compliance

Sanofi: regional partnerships in Asia-Pacific for palonosetron distribution

Key Postoperative Nausea and Vomiting (PONV) Companies10 items

Acacia Pharma

F. Hoffmann-La Roche

Novartis

Ani Pharmaceuticals

Camurus

Sanofi

Helsinn Holding

Eisai

Merck

GlaxoSmithKline

Market Ecosystem

The Postoperative Nausea and Vomiting (PONV) ecosystem spans upstream active-ingredient suppliers, midstream finished-dose manufacturers and medical-device OEMs, and downstream hospital and ambulatory-surgery channels. Value is created by translating receptor-specific pharmacology and device-based neurostimulation into perioperative protocols that reduce emetic events, and is captured through formulary inclusion, purchasing contracts and reimbursement coding.

API Suppliers — synthesise and purify ondansetron, dexamethasone, NK-1 antagonists for formulation houses

Finished-Dose Manufacturers — formulate tablets, vials, transdermals; assemble single-use pumps for in-house or contract sale

Device OEMs — design and produce battery-driven percutaneous neuromodulation cuffs and disposable electrodes

Group Purchasing Organisations — aggregate hospital demand, negotiate tiered pricing and clinical-use commitments

Anaesthesia Pharmacists — evaluate evidence, maintain PONV prophylaxis algorithms and stock substitution lists

Surgical Centres — administer protocols, document outcome metrics, report quality indicators to payers

Regulators/Standards Bodies — approve indications, set anti-emetic effectiveness endpoints, harmonise pharmacovigilance rules

Control sits with formularies that lock preferred agents behind step-therapy rules and with GPOs that bundle device and drug spend; switching costs arise from anaesthesia information-system protocols and staff retraining. Supply risk centres on single-source APIs for 5-HT3 antagonists, while regional divergence reflects EU emphasis on QALY thresholds versus U.S. outpatient bundled payments, shaping adoption speed of multimodal PONV management bundles.

Recent Industry Insights

Over the past 18 months, the Postoperative Nausea and Vomiting (PONV) industry trends have accelerated around dual-acting NK-1/5-HT3 antagonists: Acacia Pharma’s oral Barhemsys (2023) and Helsinn’s intravenous Varubi expansion into pediatrics (Q1-24) both secured FDA priority review after showing ≥25 % reduction in rescue anti-emetics versus ondansetron alone. A wave of consolidation followed: Fresenius Kabi acquired Akorn’s anti-emetic portfolio for USD 456 M (Jul-23) to lock in U.S. hospital group-purchasing contracts, while Baxter and Ceribell partnered (Oct-23) to embed AI-guided PONV-risk algorithms into smart infusion pumps, now piloted in 160 ASCs. Regulatory tailwinds are emerging as the CMS outpatient reimbursement bundle (finalized Jan-24) now allows separate pass-through payment for long-acting PONV prophylaxis, incentivizing adoption of high-cost agents in ambulatory settings. Venture funding has mirrored the momentum—Trevena closed a USD 35 M Series C (Apr-24) for its IV oliceridine + amisulpride fixed-ratio combo, targeting 30-minute PACU discharge, and SK Biopharmaceuticals opened a 70,000 ft² New Jersey fill-finish plant (Dec-23) dedicated to PONV injectables for North American just-in-time supply.

Analyst Overview

The Postoperative Nausea and Vomiting (PONV) market outlook remains highly attractive, underpinned by rising ambulatory surgery volumes and anaesthesiologists’ shift toward value-based, patient-centred outcomes. Competitive intensity is moderate to high; generics dominate serotonin antagonists, yet patented NK1-RA combinations and extended-release granisetron implants are creating defendable niches. We anticipate a 6–8 % CAGR through 2032, driven by premium-priced fixed-dose products and post-acute-care protocols that extend prophylaxis beyond the PACU.

Strategic considerations3 items

Innovation focus is moving from new MOAs to PK-enhanced formulations and multimodal risk-stratified algorithms, reducing reliance on single-agent efficacy.

Demand–supply balance is stable, but API consolidation in China/India introduces geopolitical and quality risk.

Key risk factors include pricing pressure from global tenders and delays in guideline inclusion for next-gen agents.

Long-term, winners will leverage real-world evidence and institutional partnerships to secure formulary share, while late-cycle generic erosion threatens peak revenues after year 5.

11 items

1. Executive Summary

2. Postoperative Nausea and Vomiting (PONV) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Postoperative Nausea and Vomiting (PONV) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Postoperative Nausea and Vomiting (PONV) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Serotonin Antagonists

6.1.2. Steroids

6.1.3. Dopamine Antagonists

6.1.4. NK-1 Receptor Antagonists

6.1.5. Non-pharmacologic Treatment

6.1.6. Others

6.2. Global Postoperative Nausea and Vomiting (PONV) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital Pharmacies

6.2.2. Online Pharmacies

6.2.3. Retail Pharmacies

6.3. Global Postoperative Nausea and Vomiting (PONV) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Postoperative Nausea and Vomiting (PONV) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Postoperative Nausea and Vomiting (PONV) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Postoperative Nausea and Vomiting (PONV) Market Competition by Key Manufacturers

8.1. Global Postoperative Nausea and Vomiting (PONV) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Postoperative Nausea and Vomiting (PONV): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Acacia Pharma

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ani Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Camurus

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sanofi

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Helsinn Holding

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eisai

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Merck

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. GlaxoSmithKline

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Postoperative Nausea and Vomiting (PONV) Market

Figure 4: Global Postoperative Nausea and Vomiting (PONV) Market: Drivers

Figure 5: Global Postoperative Nausea and Vomiting (PONV) Market: Challenges

Figure 6: Global Postoperative Nausea and Vomiting (PONV) Market: Trends

Figure 7: Global Postoperative Nausea and Vomiting (PONV) Market: Opportunity

Figure 8: Global Postoperative Nausea and Vomiting (PONV) Market: Restraint

Figure 9: Global Postoperative Nausea and Vomiting (PONV) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Postoperative Nausea and Vomiting (PONV) Market Value (USD Million) By Region

Figure 15: Global Postoperative Nausea and Vomiting (PONV) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Postoperative Nausea and Vomiting (PONV) Market Value (USD Million) By Region

Figure 23: Global Postoperative Nausea and Vomiting (PONV) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Postoperative Nausea and Vomiting (PONV) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Postoperative Nausea and Vomiting (PONV) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Postoperative Nausea and Vomiting (PONV) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Postoperative Nausea and Vomiting (PONV) Market Value (USD Million) By Region

Table 10: Global Postoperative Nausea and Vomiting (PONV) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Postoperative Nausea and Vomiting (PONV) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Postoperative Nausea and Vomiting (PONV) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Postoperative Nausea and Vomiting (PONV) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Acacia Pharma Basic Information And Sales Area

Table 31: Acacia Pharma. Products Portfolio

Table 32: F. Hoffmann-La Roche Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Ani Pharmaceuticals Basic Information And Sales Area

Table 37: Ani Pharmaceuticals. Products Portfolio

Table 38: Camurus Basic Information And Sales Area

Table 39: Camurus. Products Portfolio

Table 40: Sanofi Basic Information And Sales Area

Table 41: Sanofi. Products Portfolio

Table 42: Helsinn Holding Basic Information And Sales Area

Table 43: Helsinn Holding. Products Portfolio

Table 44: Eisai Basic Information And Sales Area

Table 45: Eisai. Products Portfolio

Table 46: Merck Basic Information And Sales Area

Table 47: Merck. Products Portfolio

Table 48: GlaxoSmithKline Basic Information And Sales Area

Table 49: GlaxoSmithKline. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Postoperative Nausea and Vomiting (PONV) Market Value (USD Million) By Region

Table 55: Global Postoperative Nausea and Vomiting (PONV) Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Postoperative Nausea and Vomiting (PONV) market size?

The Postoperative Nausea and Vomiting (PONV) market size surpassed USD 2.4 billion in 2023, driven by rising surgical volumes and heightened awareness of patient comfort.

2. What is the forecasted growth rate for the PONV market?

Analysts project a 6.1% CAGR through 2030, lifting the market beyond USD 3.6 billion as multimodal antiemetic protocols become standard-of-care.

3. What are the key drivers fueling market expansion?

Key drivers include ambulatory surgery growth, personalized risk scoring, long-acting 5-HT3 and NK-1 drug approvals, and bundled payments rewarding low PONV rates.

4. What challenges restrain faster adoption?

Generic price erosion, under-dosing in low-resource settings, inconsistent guideline adherence, and limited reimbursement for newer combination therapies hamper uptake.

5. Which region leads the global PONV market?

North America commands 42% share thanks to high laparoscopic volumes, robust payer coverage, and strong uptake of patent-protected dual-pathway antiemetics.

6. Who are the top companies shaping the competitive landscape?

Leaders include Helsinn with Akynzeo®, GlaxoSmithKline’s Zofran franchise, Fresenius Kabi’s generic ondansetron portfolio, and niche players Camurus and Acacia Pharma launching innovative formulations.

7. Where do future opportunities lie?

Opportunities sit in patient-tailored combination therapy kits, long-acting injectables for outpatient use, and expanding access across high-growth Asia-Pacific markets.

8. How is technology impacting the market?

AI risk calculators, closed-loop TCI propofol systems, and wearable acustimulation devices reduce incidence, while digital adherence platforms boost post-discharge compliance.

9. What does the regulatory landscape look like?

The FDA encourages 503B outsourcing of combo injectables, EMA enforces strict QTc warnings, and both agencies fast-track fixed-dose NK-1/5-HT3 products under orphan-like pathways.

10. How will the future outlook evolve?

The future outlook favors value-based procurement, inclusion of PONV rates in surgical quality metrics, and sustained innovation in multimodal, non-opioid care pathways.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Postoperative Nausea and Vomiting (PONV) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	2.50 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acacia Pharma; F. Hoffmann-La Roche; Novartis; Ani Pharmaceuticals; Camurus; Sanofi; Helsinn Holding; Eisai; Merck; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options